Condition: Hepatocellular Carcinoma (HCC) · Sponsor: Rznomics, Inc.
This study is to evaluate the safety, tolerability, efficacy and immunogenicity of RZ-001 in combination with Valganciclovir (VGCV) and Atezolizumab/Bevacizumab when given to subjects with human telomerase reverse transcriptase (hTERT)-positive HCC.
This description comes directly from the study's public registry record.
Rznomics, Inc. · +82-31-706-8730 · rznomics@rznomics.com
Always discuss trial participation with your own doctor first.
| Pusan National University Yangsan Hospital | Busan, South Korea | Recruiting |
| Kyungpook National University Hospital | Daegu, South Korea | Recruiting |
| Catholic University of Korea, Seoul St. Mary's Hospital | Seoul, South Korea | Recruiting |
| Gangnam Severance Hospital | Seoul, South Korea | Recruiting |
| Kangbuk Samsung Medical Center | Seoul, South Korea | Recruiting |
| Korea University Guro Hospital | Seoul, South Korea | Recruiting |
| Samsung Medical Center | Seoul, South Korea | Recruiting |
| Seoul National University Hospital | Seoul, South Korea | Recruiting |
| Severance Hospital | Seoul, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06695026